SUPREME COURT DENIED JUNO’S APPEAL REQUEST IN JUNO VS. KITE CASE
Santa Monica, Calif. – November 7, 2022 – We are pleased that the U.S. Supreme Court has effectively ended the Juno v. Kite case, denying Juno’s appeal. Today’s denial by the Supreme Court to hear Juno’s appeal makes the Federal Appeals Court decision, which was found in Kite’s favor, the final word on this case and ends this patent dispute.
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with manufacturing operations in North America and Europe. Kite’s singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company. For more information on Kite, please visit www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Kite, the Kite logo, and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.